Giải thích đơn giản
People with hereditary angioedema have attacks of severe swelling that arrive without warning — in the face, the limbs, the gut, or dangerously in the airway. The cause is a missing brake on one of the body's signalling systems, which lets a molecule called bradykinin accumulate and make blood vessels leak. An in vivo gene-editing treatment aims to remove a different protein in that pathway permanently, with a single infusion, so the attacks stop happening.
Tìm hiểu sâu hơn
Hereditary angioedema most often results from SERPING1 mutations causing C1-esterase inhibitor deficiency, leading to unregulated kallikrein activity and excess bradykinin. Attacks are episodic, unpredictable and potentially fatal when laryngeal. Lonvoguran ziclumeran (lonvo-z, NTLA-2002) uses lipid-nanoparticle-delivered CRISPR-Cas9 to knock out KLKB1, which encodes prekallikrein, in hepatocytes — removing the substrate upstream of bradykinin generation rather than replacing the missing inhibitor.
Why this result matters beyond the disease
Intellia reported positive results from the global Phase 3 HAELO study of lonvo-z, described by the company as the first positive Phase 3 readout for an in vivo gene-editing therapy anywhere. Enrolment completed and a biologics licence application was signalled for the second half of 2026.
Whatever happens next, the significance is structural: it is the first evidence that editing a gene inside a living person's body can carry a treatment through a registrational trial. Every in vivo programme in every other disease is watching that regulatory path.
What patients use now
Existing treatment is effective and burdensome: C1-inhibitor replacement, the kallikrein inhibitor lanadelumab, berotralstat orally, and icatibant for acute attacks. Most require indefinite regular administration. A single-dose alternative would change the shape of the disease rather than only its severity — which is why this indication attracted an editing programme despite effective drugs already existing.
Sources
- Intellia Therapeutics · 2026
Intellia reports positive Phase 3 results in hereditary angioedema ↗ - New England Journal of Medicine (Cohn et al.) · 2024
CRISPR-based therapy for hereditary angioedema ↗